Pharmac unlikely to fund EpiPen despite pleas

AUCKLAND: Allergy NZ says it is ‘beyond ridiculous’ that the life-saving EpiPen is not subsidised by Pharmac.

Pleas to fund a life-saving device continue to be ignored, and an allergy advocate says it can have “catastrophic” outcomes for families.

Allergy NZ said it was “beyond ridiculous” that Pharmac continued to deny a subsidy for the life-saving EpiPen device, which could be used when an allergy-sufferer had an anaphylactic reaction.

Allergy NZ allergy advisor Penny Jorgensen said food allergies could be catastrophic for individuals and their families, and denial of funding for the device effectively discriminated against people in lower socio-economic conditions.

“For some, it’s about food on the table or buying an EpiPen,” she said.

EpiPens cost between $120 and $180 each, and expire after two years.

As many as 1 in 10 children are thought to have food allergies, though data in New Zealand was scarce.

“It puts enormous stress on [sufferers], particularly in communities where sharing food is part of the culture.”

Pacific and Māori people were also at a particular risk of shellfish allergies. That was backed up by a 2016 NZ Health Research Council study which found those groups reporting seafood allergies at 64 per cent and 48 per cent respectively.

Pharmac operations director Lisa Williams said the difficulty with EpiPens was the high cost compared to adrenaline in other forms, such as a $1 adrenaline ampoule which could be used with a needle and syringe.

Pharmac “understood the value” in auto-injectors.

“We work within a fixed budget for medicines, which means we must make careful and considered choices about which medicines to fund that will deliver the best health outcomes.”

Another issue was that EpiPen was the only brand of auto-injector registered in New Zealand by medicine and devices regulatory body Medsafe.

“[That] is why the supplier, Mylan is able to set a high price.”

But Jorgensen said Pharmac wasn’t working and it was passing the cost on to families and communities.

It was unreasonable to expect a parent or teacher to administer adrenaline by a syringe in an emergency, let alone a child or adult having a reaction.

“You can’t take your time, you have a couple of minutes, max. You have to break the ampoule, measure it up, assemble the needle and syringe, all in an emergency situation, while people are panicking or while having a reaction.”

NZ Clinical Immunology and Allergy Group’s chairperson Dr Maia Brewerton said considering food allergies could be fatal, all patients with a life-threatening food allergy should carry an EpiPen and have an anaphylaxis action plan.

“The lack of funded Epipens in New Zealand needs to be addressed.”